Development of rifapentine susceptibility tests for Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 1, 1999, Pages 25-28

  Heifets, L ^a   Sanchez, T ^a   Vanderkolk, J ^a   Pham, V ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; RIFAPENTINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL LABORATORY; CONTROLLED STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RADIOMETRY;

EID: 0032911952     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.1.25     Document Type: Article

References (13)

1. Arioli, V., M. Berti, G. Carniti, E. Randisi, E. Rossi, and R. Scotti. 1981. Antibacterial activity of DL473, a new semisynthetic rifamycin derivative. J. Antibiot. (Tokyo) 34:1026-1029.
2. Dhillon, J., J. M. Dickinson, A. J. Gay, T. K. Ng, and D. A. Mitchison. 1989. Activity of two long lasting rifamycins, rifapentine and FCE22807, in experimental murine tuberculosis. Tubercle Lung Dis. 73:116-123.
3. Dhillon, J., and D. A. Mitchison. 1992. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am. Rev. Respir. Dis. 145:212-214.
4. Dickinson, J. M., and D. A. Mitchison. 1987. In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle 68:113-119.
5. Heifets, L. 1996. Drug susceptibility testing in mycobacteriology, p. 641-656. In L. Heifets (ed.), Clinics in laboratory medicine: clinical mycobacteriology, vol. 16. The W. B. Saunders Co., Philadelphia, Pa.
6. Heifets, L. B. 1991. Drug susceptibility tests in the management of chemotherapy of tuberculosis, p. 89-121. In L. B. Heifets (ed.), Drug susceptibility in the chemotherapy of mycobacterial infections. CRC Press, Inc., Boca Raton, Fla.
7. Heifets, L. B., P. J. Lindholm-Levy, and M. A. Flory. 1990. Bactericidal activity in vitro of various rifamycins against M. avium and M. tuberculosis. Am. Rev. Respir. Dis. 141:626-630.
8. Ji, B., C. Truffot-Pernot, C. Lacroix, M. C. Raviglione, R. J. O'Brien, P. Olliaro, G. Roscigno, and J. Grosset. 1991. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob. Agents Chemother. 35:579-581.
9. Mor, N., B. Simon, N. Mezo, and L. Heifets. 1995. Comparison of the activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob. Agents Chemother. 39:2073-2077.
10. Pascual, A., D. Tsukayama, J. Kovarik, G. Gekker, and P. Peterson. 1987. Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes. Eur. J. Clin. Microbiol. 6:152-157.
11. Truffot-Pernot, C. H., J. Grosset, R. Bismuth, and H. L. Lecoeur. 1983. Activité de la rifapicine administrée de maniére intermittente et de la cyclopentyl rifamycine (ou DL473) sur la tuberculose expérimentale de la souris. Rev. Fr. Mal. Respir. 11:875-882.
12. Tsukamura, M., S. Mizuno, and H. Toyama. 1986. In vitro antimycobacterial activity of rifapentine (comparison with rifampicin). Kekkaku 61:633-639.
13. Yates, M. D., and C. H. Collins. 1982. Comparison of the sensitivity of mycobacteria to the cyclopentyl rifamycin DL473 and rifamycin. J. Antimicrob. Chemother. 10:147-150.